Renaissance Capital logo

Comera Life Sciences (OTR Acquisition) Priced, Nasdaq: CMRA

Blank check company formed by the co-founder of Cyrus Capital and Standard General (completed 5/20/2022).

Industry: SPAC

First Day Return: -0.5%

Industry: SPAC

We are a newly organized blank check company. Our sponsor is controlled by affiliates of Nicholas J. Singer, our Chairman and Chief Executive Officer, and Purchase Capital LLC, an investment firm founded by Mr. Singer. Purchase Capital serves as Mr. Singer’s family office and sponsor to leading institutional investors and third-party family offices. Purchase Capital provides patient capital for private and public companies that have significant potential for long-term value creation. Mr. Singer has also had a highly successful parallel career as an entrepreneur. He was Co-Founder of two successful asset management businesses, Cyrus Capital, a registered investment advisor with $5 billion AUM and Standard General, a registered investment advisor with $1 billion AUM. Consistent with our strategy, we have identified the following general criteria and guidelines which we believe are important in evaluating prospective target businesses. We will use these criteria and guidelines in evaluating acquisition opportunities and will initially target businesses with enterprise values of approximately $750 million to $2.5 billion, but we may decide to enter into our initial business combination with a target business that does not meet these criteria and guidelines.
more less
IPO Data
IPO File Date 08/18/2020
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 10.0
Deal Size ($mm) $100
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 11/17/2020
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $100
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Miami, FL, United States
Founded 2020
Employees at IPO 1

Comera Life Sciences (OTR Acquisition) (CMRA) Performance